

1 **eTable 5. pRNFL-z predicting future disease activity at two-year follow-up in Sys4MS cohort**

	EDSS Worsening	Clinical Relapse	New Brain Lesions	EDA-3
	OR [95%CI], p-value			
pRNFL-z (continuous)	0.66 [0.47 – 0.95], p = 0.024	0.89 [0.63 – 1.27], p = 0.524	0.87 [0.61 – 1.24], p = 0.436	0.74 [0.55 – 1.01], p = 0.055
pRNFL-z (continuous) (Reciprocal OR)	1.51 [1.06 – 2.15], p = 0.024	1.12 [0.78 – 1.59], p = 0.524	1.15 [0.81 – 1.65], p = 0.436	1.35 [0.98 – 1.83], p = 0.055
Female	1.61 [0.68 – 3.62], p = 0.281	1.00 [0.79 – 3.34], p = 0.995	1.02 [0.41 – 2.53], p = 0.959	1.01 [0.47 – 2.16], p = 0.980
Baseline EDSS	0.94 [0.71 – 1.24], p = 0.662	1.21 [0.92 – 1.60], p = 0.171	0.93 [0.69 – 1.26], p = 0.649	1.05 [0.82 – 1.35], p = 0.683
Disease duration	1.03 [0.97 – 1.08], p = 0.355	0.97 [0.91 – 1.03], p = 0.292	1.00 [0.94 – 1.06], p = 0.919	0.99 [0.95 – 1.05], p = 0.807
Received DMT	0.52 [0.21 – 1.28], p = 0.153	1.11 [0.41 – 2.98], p = 0.834	0.79 [0.31 – 2.02], p = 0.624	0.62 [0.27 – 1.40], p = 0.248

2 Abbreviations: DMT: disease-modifying therapies; EDA-3: evidence of disease activity; EDSS: Expanded
3 Disability Status Scale; OR: odds ratio; pRNFL-z: peripapillary retinal nerve fiber layer thickness age-adjusted
4 z-score.